Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Nucleic Acids Res ; 51(D1): D621-D628, 2023 01 06.
Article in English | MEDLINE | ID: mdl-36624664

ABSTRACT

Quantitative activity and species source data of natural products (NPs) are important for drug discovery, medicinal plant research, and microbial investigations. Activity values of NPs against specific targets are useful for discovering targeted therapeutic agents and investigating the mechanism of medicinal plants. Composition/concentration values of NPs in individual species facilitate the assessments and investigations of the therapeutic quality of herbs and phenotypes of microbes. Here, we describe an update of the NPASS natural product activity and species source database previously featured in NAR. This update includes: (i) new data of ∼95 000 records of the composition/concentration values of ∼1 490 NPs/NP clusters in ∼390 species, (ii) extended data of activity values of ∼43 200 NPs against ∼7 700 targets (∼40% and ∼32% increase, respectively), (iii) extended data of ∼31 600 species sources of ∼94 400 NPs (∼26% and ∼32% increase, respectively), (iv) new species types of ∼440 co-cultured microbes and ∼420 engineered microbes, (v) new data of ∼66 600 NPs without experimental activity values but with estimated activity profiles from the established chemical similarity tool Chemical Checker, (vi) new data of the computed drug-likeness properties and the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties for all NPs. NPASS update version is freely accessible at http://bidd.group/NPASS.


Subject(s)
Biological Products , Biomedical Research , Databases, Factual , Drug Discovery , Pharmaceutical Preparations/isolation & purification
2.
PLoS Biol ; 18(3): e3000688, 2020 03.
Article in English | MEDLINE | ID: mdl-32218572

ABSTRACT

Obesity leads to multiple health problems, including diabetes, fatty liver, and even cancer. Here, we report that urolithin A (UA), a gut-microflora-derived metabolite of pomegranate ellagitannins (ETs), prevents diet-induced obesity and metabolic dysfunctions in mice without causing adverse effects. UA treatment increases energy expenditure (EE) by enhancing thermogenesis in brown adipose tissue (BAT) and inducing browning of white adipose tissue (WAT). Mechanistically, UA-mediated increased thermogenesis is caused by an elevation of triiodothyronine (T3) levels in BAT and inguinal fat depots. This is also confirmed in UA-treated white and brown adipocytes. Consistent with this mechanism, UA loses its beneficial effects on activation of BAT, browning of white fat, body weight control, and glucose homeostasis when thyroid hormone (TH) production is blocked by its inhibitor, propylthiouracil (PTU). Conversely, administration of exogenous tetraiodothyronine (T4) to PTU-treated mice restores UA-induced activation of BAT and browning of white fat and its preventive role on high-fat diet (HFD)-induced weight gain. Together, these results suggest that UA is a potent antiobesity agent with potential for human clinical applications.


Subject(s)
Adipose Tissue, Brown/metabolism , Anti-Obesity Agents/therapeutic use , Coumarins/therapeutic use , Obesity/prevention & control , Adipocytes, Brown/drug effects , Adipocytes, Brown/metabolism , Adipocytes, White/drug effects , Adipocytes, White/metabolism , Adipose Tissue, White/metabolism , Animals , Diet, High-Fat/adverse effects , Energy Metabolism/drug effects , Fatty Liver/prevention & control , Glucose Intolerance/prevention & control , Insulin Resistance , Maillard Reaction , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Obesity/metabolism , Propylthiouracil/toxicity , Thermogenesis , Triiodothyronine/antagonists & inhibitors , Triiodothyronine/metabolism , Weight Gain/drug effects
3.
FASEB J ; 34(5): 6688-6702, 2020 05.
Article in English | MEDLINE | ID: mdl-32212192

ABSTRACT

Mitochondrial aconitase (Aco2) catalyzes the conversion of citrate to isocitrate in the TCA cycle, which produces NADH and FADH2, driving synthesis of ATP through OXPHOS. In this study, to explore the relationship between adipogenesis and mitochondrial energy metabolism, we hypothesize that Aco2 may play a key role in the lipid synthesis. Here, we show that overexpression of Aco2 in 3T3-L1 cells significantly increased lipogenesis and adipogenesis, accompanied by elevated mitochondrial biogenesis and ATP production. However, when ATP is depleted by rotenone, an inhibitor of the respiratory chain, the promotive role of Aco2 in adipogenesis is abolished. In contrast to Aco2 overexpression, deficiency of Aco2 markedly reduced lipogenesis and adipogenesis, along with the decreased mitochondrial biogenesis and ATP production. Supplementation of isocitrate efficiently rescued the inhibitory effect of Aco2 deficiency. Similarly, the restorative effect of isocitrate was abolished in the presence of rotenone. Together, these results show that Aco2 sustains normal adipogenesis through mediating ATP production, revealing a potential mechanistic link between TCA cycle enzyme and lipid synthesis. Our work suggest that regulation of adipose tissue mitochondria function may be a potential way for combating abnormal adipogenesis related diseases such as obesity and lipodystrophy.


Subject(s)
Aconitate Hydratase/metabolism , Adenosine Triphosphate/metabolism , Adipogenesis , Adipose Tissue/cytology , Mitochondria/enzymology , 3T3-L1 Cells , Aconitate Hydratase/genetics , Adipose Tissue/metabolism , Animals , Male , Mice , Mice, Inbred C57BL
4.
Cells ; 9(2)2020 01 31.
Article in English | MEDLINE | ID: mdl-32023857

ABSTRACT

The prevalence of obesity has increased dramatically worldwide in the past ~50 years. Searching for safe and effective anti-obesity strategies are urgently needed. Lactucin, a plant-derived natural small molecule, is known for anti-malaria and anti-hyperalgesia. The study is to investigate whether lactucin plays a key role in adipogenesis. To this end, in vivo male C57BL/6 mice fed a high-fat diet (HFD) were treated with 20 mg/kg/day of lactucin or vehicle by gavage for seven weeks. Compared with vehicle-treated controls, Lactucin-treated mice showed lower body mass and mass of adipose tissue. Consistently, in vitro 3T3-L1 cells were treated with 20 µM of lactucin. Compared to controls, lactucin-treated cells showed significantly less lipid accumulation during adipocyte differentiation and lower levels of lipid synthesis markers. Mechanistically, we showed the anti-adipogenic property of lactucin was largely limited to the early stage of adipogenesis. Lactucin-treated cells fail to undergo mitotic clonal expansion (MCE). Further studies demonstrate that lactucin-induced MCE arrests might result from reduced phosphorylation of JAK2 and STAT3. We then asked whether activation of JAK2/STAT3 would restore the inhibitory effect of lactucin on adipogenesis with pharmacological STAT3 activator colivelin. Our results revealed similar levels of lipid accumulation between lactucin-treated cells and controls in the presence of colivelin, indicating that inactivation of STAT3 is the limiting factor for the anti-adipogenesis of lactucin in these cells. Together, our results provide the indication that lactucin exerts an anti-adipogenesis effect, which may open new therapeutic options for obesity.


Subject(s)
Adipogenesis/drug effects , Dietary Supplements , Down-Regulation/drug effects , Janus Kinase 2/metabolism , Lactones/pharmacology , Mitosis/drug effects , Phorbols/pharmacology , STAT3 Transcription Factor/metabolism , Sesquiterpenes/pharmacology , Signal Transduction , 3T3-L1 Cells , Adipocytes/drug effects , Adipocytes/metabolism , Adipogenesis/genetics , Animals , Cell Cycle Checkpoints/drug effects , Cell Proliferation/drug effects , Clone Cells , Diet, High-Fat , Down-Regulation/genetics , Gene Expression Regulation/drug effects , Hyperglycemia/genetics , Hyperglycemia/pathology , Lactones/chemistry , Male , Mice , Mice, Inbred C57BL , Obesity/genetics , Obesity/pathology , Phorbols/chemistry , Sesquiterpenes/chemistry , Signal Transduction/drug effects , Triglycerides/biosynthesis
5.
Molecules ; 22(6)2017 May 26.
Article in English | MEDLINE | ID: mdl-28587109

ABSTRACT

Oxidative damage can lead to a wide range of diseases. Nrf2 is an important transcription factor that regulates many of the cytoprotective enzymes involved in the oxidative stress response. Therefore, targeting the regulation of Nrf2 activation is one logical and effective strategy to prevent or lower the risk of oxidative stress-related diseases. Until now, most research has focused on electrophilic indirect Nrf2 activators, but the risk of 'off-target' effects may be associated with these activators. To find novel small non-electrophilic modulators of Nrf2, we started from chemical agents derived from a connectivity map (cMap) and identified 22 non-electrophilic potential Nrf2-activating drugs through a drug repositioning tactic. By determining the expression changes of antioxidant genes in MCF7 cells that were treated with the potential Nrf2 activators using quantitative real-time polymerase chain reaction RT-PCR (real-time polymerase chain reaction) (qRT-PCR), astemizole was found to have a greater scale of upregulating antioxidant genes NQO1, HO-1, and GCLM than the positive control d,l-sulforaphane, although the testing concentration was lower than that of the control. Astemizole is a good potential redox regulator and deserves more pharmacodynamic experimentation to test and verify its feasibility for use as an Nrf2 activator.


Subject(s)
Drug Discovery , NF-E2-Related Factor 2/agonists , Antioxidants/pharmacology , Cell Line, Tumor , Drug Evaluation, Preclinical , Drug Repositioning , Gene Expression Regulation/drug effects , Humans , NF-E2-Related Factor 2/metabolism , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects
6.
Biochem Biophys Res Commun ; 466(3): 400-5, 2015 Oct 23.
Article in English | MEDLINE | ID: mdl-26365351

ABSTRACT

Based upon many theoretical findings on protein evolution, we proposed a ligand-selection model for the origin of proteins, in which the most ancient proteins originated from ATP selection in a pool of random peptides. To test this ligand-selection model, we constructed a random peptide library consisting of 15 types of prebiotic amino acids and then used cDNA display to perform six rounds of in vitro selection with ATP. By means of next-generation sequencing, the most prevalent sequence was defined. Biochemical and biophysical characterization of the selected peptide showed that it was stable and foldable and had ATP-hydrolysis activity as well.


Subject(s)
Adenosine Triphosphate/chemistry , Amino Acids/chemistry , Peptide Library , Peptides/chemistry , Prebiotics , Computational Biology , DNA, Complementary/metabolism , Gene Library , High-Throughput Nucleotide Sequencing , Hydrolysis , Ligands , Protein Binding , Proteins/chemistry , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL